Publications Database

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental condition that frequently persists into adulthood and is linked to alterations in fronto-striatal circuitry and dopaminergic signaling. Brain iron is essential for dopamine synthesis and neural metabolism and can be indexed in vivo using quantitative susceptibility mapping (QSM), which reflects regional magnetic susceptibility. [...]

The prevailing view frames microglia and macrophages as guardians against amyloid beta (Aβ) accumulation in Alzheimer's disease (AD). Here, we overturn this paradigm by demonstrating that human phagocytic cells, including differentiated THP-1 macrophages and hESC-derived microglia, are not merely passive responders but active producers of extracellular, seeding-competent Aβ42 fibrils, the amyloid species most strongly linked to parenchymal plaque formation and neurodegeneration. [...]

Seit mehr als siebzig Jahren verlaufen Neurologie und Psychiatrie in Deutschland zunehmend auf getrennten Gleisen, teils gewachsen aus der Annahme, dass das „Seelische“ und das „Körperliche“ unterschiedlichen Gesetzmäßigkeiten folgen. Im 21. [...]

The mechanisms mediating elite and persistent HIV control in people living with HIV (PLHIV) are only partially understood and largely attributed to adaptive T cell responses, but whether innate immunity also contributes remains unclear. Using samples from the 2000HIV study, we examined the transcriptional and functional profiles of monocytes from spontaneous HIV controllers and normal progressors on long-term antiretroviral therapy. [...]

Recent studies have demonstrated that eye tracking is a valuable tool in the detection, classification and staging of neurodegenerative diseases such as Parkinson's Disease (PD). However, traditional methods for capturing gaze data often rely on expensive and non-engaging clinical equipment such as video-oculography, limiting their accessibility and scalability. [...]

Antipsychotic drugs are the established treatment for acute schizophrenia but differ in receptor-binding profiles. In 2024, a new-in-class muscarinic receptor agonist (xanomeline-trospium) was licenced, acting upstream of antidopaminergic agents, and providing hope to decrease the adverse effects burden of antipsychotics. [...]